|
Time points
|
Intervention
|
Control
|
Lactate
|
|---|
|
Baseline
|
Vasopressors
|
9
|
9
|
| |
Vasopressor dose (μg/kg/min)
|
0.04 ± 0.06
|
0.07 ± 0.1
|
| |
Levosimendan (0.1 μg/kg/min)
|
5
|
4
|
| |
Dobutamine
|
1
|
0
|
| |
IABP
|
2
|
4
|
| |
Invasive ventilation
|
10
|
14
|
| |
Noninvasive ventilation
|
5
|
1
|
|
24 hours
|
Vasopressors
|
7
|
3
|
| |
Vasopressor dose (μg/kg/min)
|
0.03 ± 0.05
|
0.03 ± 0.1
|
| |
IABP
|
2
|
4
|
| |
Invasive ventilation
|
9
|
10
|
| |
Noninvasive ventilation
|
5
|
0
|
|
48 hours
|
Vasopressors
|
2
|
3
|
| |
Vasopressor dose (μg/kg/min)
|
0.01 ± 0.03
|
0.04 ± 0.1
|
| |
IABP
|
2
|
3
|
| |
Invasive ventilation
|
4
|
9
|
| |
Noninvasive ventilation
|
1
|
2
|
- aIABP = Intraaortic balloon counterpulsation device. Vasopressors are noradrenaline or adrenaline. Levosimendan (12.5 mg) was administered at 0.1 μg/kg/min over the course of 24 hours during the study period. Infusions were always started prior to study enrolment. All data are expressed as number of patients, except for vasopressor dose, for which data are expressed as mean ± SD.
